How to manage intolerance to dopamine agonist in patients with prolactinoma

Imagem de Miniatura
Arquivos
art_STUMPF_How_to_manage_intolerance_to_dopamine_agonist_in_2023.PDF (1.14 MB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER
Autores
Citação
PITUITARY, v.26, n.2, p.187-196, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
PurposeDopamine agonists (DA) are the gold-standard for prolactinoma and hyperprolactinemia treatment. Intolerance to DA leading to drug drop out occurs in 3 to 12% of cases. We provide here a review of published data about DA intolerance and present a case report concerning the use of intravaginal cabergoline.MethodsWe review the literature on the definition, the pathogenesis, frequency and management of DA intolerance. In addition, the review provides strategies to enhance tolerability and avoid precocious clinical treatment withdrawal.ResultsCabergoline is often cited as the most tolerable DA and its side effects tend to ameliorate within days to weeks. Restarting the same drug at a lower dose or switching to another DA can be used in cases of intolerance. The vaginal route can be tried specifically if there are gastrointestinal side effects in the oral administration. Symptomatic treatment could be attempted, although mainly based on a strategy used in other diseases.ConclusionsDue to limited data, no guidelines have been developed for the management of intolerance in DA treatment. The most frequent management is to perform transsphenoidal surgery. Nevertheless, this manuscript provides data derived from published literature and expert opinion, suggesting new approaches to this clinical issue.
Palavras-chave
Prolactinoma, Hyperprolactinemia, Cabergoline, Bromocriptine, Dopamine agonist, Intolerance, Corticosteroid
URI
https://observatorio.fm.usp.br/handle/OPI/54920
Referências
  1. [Anonymous], 2008, MIDDLE EAST FERTIL S
  2. Auriemma RS, 2019, NEUROENDOCRINOLOGY, V109, P34, DOI 10.1159/000499470
  3. Babey M, 2011, PITUITARY, V14, P222, DOI 10.1007/s11102-010-0283-y
  4. Beccuti G, 2021, J ENDOCRINOL INVEST, V44, P1699, DOI 10.1007/s40618-020-01478-0
  5. BEREZIN M, 1991, ISRAEL J MED SCI, V27, P375
  6. Boguszewski CL, 2019, BEST PRACT RES CL EN, V33, DOI 10.1016/j.beem.2019.04.002
  7. Bonert V, 2020, PITUITARY, V23, P307, DOI 10.1007/s11102-020-01039-x
  8. BRONSTEIN MD, 1987, HORM METAB RES, V19, P271, DOI 10.1055/s-2007-1011796
  9. BRUE T, 1992, J CLIN ENDOCR METAB, V74, P577, DOI 10.1210/jc.74.3.577
  10. CICCARELLI E, 1988, FERTIL STERIL, V49, P589
  11. Cicinelli E, 1996, J ENDOCRINOL INVEST, V19, P427, DOI 10.1007/BF03349887
  12. Colao A, 1997, J CLIN ENDOCR METAB, V82, P3574, DOI 10.1210/jc.82.11.3574
  13. Colao A, 2000, J CLIN ENDOCR METAB, V85, P2247, DOI 10.1210/jc.85.6.2247
  14. Coopmans EC, 2019, EUR J ENDOCRINOL, V181, pK21, DOI 10.1530/EJE-19-0279
  15. Portari LHC, 2022, NEUROENDOCRINOLOGY, V112, P68, DOI 10.1159/000514591
  16. Crocker AD, 1994, AUST PRESCR, P17
  17. CROSIGNANI PG, 1982, FERTIL STERIL, V37, P61
  18. Darwish AM, 2005, FERTIL STERIL, V83, P1053, DOI 10.1016/j.fertnstert.2004.09.024
  19. Darwish AM, 2008, FERTIL STERIL, V90, P1864, DOI 10.1016/j.fertnstert.2007.09.029
  20. de Luis DA, 2000, J ENDOCRINOL INVEST, V23, P428, DOI 10.1007/BF03343751
  21. De Sousa SMC, 2020, J CLIN ENDOCR METAB, V105, pE108, DOI 10.1210/clinem/dgz076
  22. Deane AM, 2019, NUTR CLIN PRACT, V34, P23, DOI 10.1002/ncp.10199
  23. Di Sarno A, 2000, CLIN ENDOCRINOL, V53, P53, DOI 10.1046/j.1365-2265.2000.01016.x
  24. DURANTEAU L, 1991, CLIN ENDOCRINOL, V34, P25, DOI 10.1111/j.1365-2265.1991.tb01731.x
  25. ESPINOS JJ, 1994, FERTIL STERIL, V62, P926
  26. Fachi MM, 2021, J CLIN PHARM THER, V46, P1549, DOI 10.1111/jcpt.13460
  27. Ferrari CI, 1997, CLIN ENDOCRINOL, V46, P409, DOI 10.1046/j.1365-2265.1997.1300952.x
  28. Freeman R, 2018, J AM COLL CARDIOL, V72, P1294, DOI 10.1016/j.jacc.2018.05.079
  29. Friesen H G, 1977, Clin Endocrinol (Oxf), V6 Suppl, p91S
  30. GINSBURG J, 1992, GYNECOL ENDOCRINOL, V6, P119, DOI 10.3109/09513599209046395
  31. GIUSTI M, 1994, J ENDOCRINOL INVEST, V17, P51, DOI 10.1007/BF03344963
  32. Hamidianjahromi A, 2022, REV ENDOCR METAB DIS, V23, P1089, DOI 10.1007/s11154-022-09753-6
  33. Heckroth M, 2021, J CLIN GASTROENTEROL, V55, P279, DOI 10.1097/MCG.0000000000001485
  34. HOMBURG R, 1990, CLIN ENDOCRINOL, V32, P565, DOI 10.1111/j.1365-2265.1990.tb00899.x
  35. Honegger J, 2020, PITUITARY, V23, P45, DOI 10.1007/s11102-019-01016-z
  36. Ioachimescu AG, 2019, EUR J ENDOCRINOL, V180, P31, DOI 10.1530/EJE-18-0682
  37. Ivan Gabriella, 2005, Endocrine, V28, P101, DOI 10.1385/ENDO:28:1:101
  38. Iyer Pallavi, 2011, Endocr Pract, V17, pe55, DOI 10.4158/EP10369.CR
  39. Jasonni VM, 1991, ACTA OBSTET GYN SCAN, V70, P493, DOI 10.3109/00016349109007166
  40. Jenkins PJ, 1996, CLIN ENDOCRINOL, V45, P447, DOI 10.1046/j.1365-2265.1996.8240834.x
  41. KATZ E, 1989, OBSTET GYNECOL, V73, P517
  42. Kelley BJ, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/603631
  43. Kim D, 2020, EUR J ENDOCRINOL, V182, P177, DOI 10.1530/EJE-19-0753
  44. KISSNER DG, 1980, NEW ENGL J MED, V302, P749
  45. KLEINBERG DL, 1983, NEW ENGL J MED, V309, P704, DOI 10.1056/NEJM198309223091205
  46. KLETZKY OA, 1989, FERTIL STERIL, V51, P269
  47. LAMBERTS SWJ, 1991, J CLIN ENDOCR METAB, V72, P635, DOI 10.1210/jcem-72-3-635
  48. Lasolle H, 2019, ANN ENDOCRINOL-PARIS, V80, P84, DOI 10.1016/j.ando.2018.07.013
  49. Lin SJ, 2017, J CLIN ENDOCR METAB, V102, P3692, DOI 10.1210/jc.2017-00627
  50. Lin SJ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.955100
  51. Liu XH, 2018, WORLD NEUROSURG, V115, P94, DOI 10.1016/j.wneu.2018.02.188
  52. MALCHOFF CD, 1986, J CLIN ENDOCR METAB, V63, P197, DOI 10.1210/jcem-63-1-197
  53. MANESCHI F, 1977, LANCET, V2, P462
  54. Melmed S, 2011, J CLIN ENDOCR METAB, V96, P273, DOI 10.1210/jc.2010-1692
  55. MEROLA B, 1994, GYNECOL ENDOCRINOL, V8, P175, DOI 10.3109/09513599409072452
  56. MEROLA B, 1991, GYNECOL ENDOCRINOL, V5, P267, DOI 10.3109/09513599109028448
  57. MEROLA B, 1992, J ENDOCRINOL INVEST, V15, P173, DOI 10.1007/BF03348700
  58. MORO M, 1991, HORM RES, V35, P137, DOI 10.1159/000181889
  59. Motta T, 1996, FERTIL STERIL, V65, P440, DOI 10.1016/S0015-0282(16)58113-8
  60. NEWMAN CB, 1989, CLIN ENDOCRINOL, V31, P391, DOI 10.1111/j.1365-2265.1989.tb01263.x
  61. Nunes VD, 2011, PITUITARY, V14, P259, DOI 10.1007/s11102-010-0290-z
  62. Ono M, 2010, J CLIN ENDOCR METAB, V95, P2672, DOI 10.1210/jc.2009-2605
  63. Ono M, 2008, J CLIN ENDOCR METAB, V93, P4721, DOI 10.1210/jc.2007-2758
  64. Orrego J J, 2000, Pituitary, V3, P251, DOI 10.1023/A:1012836331506
  65. PARKES D, 1979, NEW ENGL J MED, V301, P873
  66. Pascal-Vigneron V, 1983, PRESSE MEDICALE PARI, V24, P753
  67. Peixoto AJ, 2022, CLEV CLIN J MED, V89, P36, DOI 10.3949/ccjm.89gr.22001
  68. Rastogi A, 2013, CLIN ENDOCRINOL, V79, P409, DOI 10.1111/cen.12149
  69. Raverot G, 2019, EUR J ENDOCRINOL, V181, pC1, DOI 10.1530/EJE-19-0359
  70. Roila F, 2016, ANN ONCOL, V27, pv119, DOI 10.1093/annonc/mdw270
  71. ROJANASAKUL A, 1990, Journal of the Medical Association of Thailand, V73, P42
  72. Sabuncu T, 2001, INTERNAL MED, V40, P857, DOI 10.2169/internalmedicine.40.857
  73. Sari R, 2021, HORM METAB RES, V53, P413, DOI 10.1055/a-1525-2131
  74. Schultz P N, 2000, Pituitary, V3, P239, DOI 10.1023/A:1012884214668
  75. Souteiro P, 2020, PITUITARY, V23, P27, DOI 10.1007/s11102-019-00987-3
  76. Stiles CE, 2021, ANN ENDOCRINOL-PARIS, V82, P182, DOI 10.1016/j.ando.2020.02.007
  77. STRACKE H, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1834
  78. Tamagno G, 2007, EUR J OBSTET GYN R B, V135, P139, DOI 10.1016/j.ejogrb.2007.05.004
  79. Tonini M, 2004, ALIMENT PHARM THER, V19, P379, DOI 10.1111/j.1365-2036.2004.01867.x
  80. VANCE ML, 1989, J CLIN ENDOCR METAB, V68, P336, DOI 10.1210/jcem-68-2-336
  81. VANDERHEIJDEN PFM, 1991, EUR J OBSTET GYN R B, V40, P111, DOI 10.1016/0028-2243(91)90101-P
  82. VANDERLELY AJ, 1991, J CLIN ENDOCR METAB, V72, P1136, DOI 10.1210/jcem-72-5-1136
  83. Verhelst J, 1999, J CLIN ENDOCR METAB, V84, P2518, DOI 10.1210/jc.84.7.2518
  84. VERHELST JA, 1991, ACTA ENDOCRINOL-COP, V125, P385, DOI 10.1530/acta.0.1250385
  85. VERMESH M, 1988, OBSTET GYNECOL, V72, P693
  86. VETR M, 1990, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V125, P155
  87. Vilar L, 2008, J ENDOCRINOL INVEST, V31, P436, DOI 10.1007/BF03346388
  88. VILAR L, 1994, CLIN ENDOCRINOL, V41, P821, DOI 10.1111/j.1365-2265.1994.tb02799.x
  89. WEBSTER J, 1993, CLIN ENDOCRINOL, V39, P323, DOI 10.1111/j.1365-2265.1993.tb02372.x
  90. WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403
  91. Webster J, 1996, DRUG SAFETY, V14, P228, DOI 10.2165/00002018-199614040-00003
  92. Wong A, 2015, J CLIN NEUROSCI, V22, P1568, DOI 10.1016/j.jocn.2015.03.059
  93. Yagnik KJ, 2021, PITUITARY, V24, P978, DOI 10.1007/s11102-021-01188-7
  94. Zanettini R, 2007, NEW ENGL J MED, V356, P39, DOI 10.1056/NEJMoa054830

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/25
Artigos e Materiais de Revistas Científicas - LIM/62